81 FR 6451 - Schedules of Controlled Substances: Table of Excluded Nonnarcotic Products: Vicks® VapoInhaler®
DEPARTMENT OF JUSTICE
Drug Enforcement Administration Federal Register Volume 81, Issue 25 (February 8, 2016)
Drug Enforcement Administration
Federal Register Volume 81, Issue 25 (February 8, 2016)
| Page Range | 6451-6453 | |
| FR Document | 2016-02403 |
[Federal Register Volume 81, Number 25 (Monday, February 8, 2016)] [Rules and Regulations] [Pages 6451-6453] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-02403] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration 21 CFR Part 1308 [Docket No. DEA-367] RIN 1117-AB39 Schedules of Controlled Substances: Table of Excluded Nonnarcotic Products: Vicks[supreg] VapoInhaler[supreg] AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Final rule. ----------------------------------------------------------------------- SUMMARY: This final rule adopts the interim final rule, with a correction to spelling of the manufacturer's name that was published in the Federal Register on October 27, 2015. The Drug Enforcement Administration is amending the table of Excluded Nonnarcotic Products to update the listing for Vicks[supreg] VapoInhaler[supreg], containing 50 mg levmetamfetamine in a nasal decongestant inhaler, marketed by The Procter & Gamble Company. This over-the-counter, non-narcotic drug product is excluded from provisions of the Controlled Substances Act. DATES: This final rule is effective on February 8, 2016. FOR FURTHER INFORMATION CONTACT: Barbara J. Boockholdt, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 598-6812. SUPPLEMENTARY INFORMATION: Legal Authority The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. 21 U.S.C. 801-971. Titles II and III are referred to as the ``Controlled Substances Act'' and the ``Controlled Substances Import and Export Act,'' respectively, and they are collectively referred to as the ``Controlled Substances Act'' or the ``CSA'' for the purpose of this action. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), chapter II. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while ensuring an adequate supply is available for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety. Under the CSA, each controlled substance is classified into one of five schedules based upon its potential for abuse, its currently accepted medical use in treatment in the United States, and the degree of dependence the drug or other substance may cause. 21 U.S.C. 812. The initial schedules of controlled substances established by Congress are found at 21 U.S.C. 812(c) and the current list of all scheduled substances is published at 21 CFR part 1308. The CSA states that the Attorney General shall by regulation exclude any nonnarcotic drug which contains a controlled substance from the application of the CSA, if such drug may, under the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 301 et seq., be lawfully sold over-the-counter without a prescription. 21 U.S.C. 811(g)(1). Such exclusions apply only to specific nonnarcotic drugs following suitable application to the DEA in accordance with 21 CFR 1308.21. The current table of Excluded Nonnarcotic Products is found in 21 CFR 1308.22. The authority to exclude such substances has been delegated to the Administrator of the DEA, 28 CFR 0.100, and redelegated to the Deputy Assistant Administrator of the Office of Diversion Control, section 7 of 28 CFR part 0, appendix to subpart R. Background This final rule adopts, with a change to the spelling of the manufacturer's name, the interim final rule, ``Schedules of Controlled Substances: Table of Excluded Nonnarcotic Products: Vicks[supreg] VapoInhaler[supreg] '' that was published in the Federal Register on October 27, 2015. 80 FR 65635. The correct spelling of the manufacturer's name is ``The Procter & Gamble Company.'' The [[Page 6452]] interim final rule contained a typographical error in which ``Procter'' was inadvertently spelled as ``Proctor.'' On February 9, 2012, pursuant to the application process of Sec. 1308.21, the DEA received correspondence from The Procter & Gamble Company (``P&G'') notifying the DEA that it had reduced the quantity of l-desoxyephedrine (levmetamfetamine) from 113 mg to 50 mg in their Vicks[supreg] Inhaler\TM\ product which is currently excluded under Sec. 1308.22. Levmetamfetamine is controlled in schedule II as an isomer of methamphetamine. 21 CFR 1308.12(d)(2). P&G requested that the DEA update the current exclusion for its Vicks[supreg] Inhaler\TM\ and indicated it had acquired Richardson-Vicks, Inc. (including its subsidiary, the Vick Chemical Company). The company stated that the product name has been modified from Vicks[supreg] Inhaler\TM\ to Vicks[supreg] VapoInhaler[supreg] and that the change included a corresponding National Drug Code (NDC) number reassignment by the U.S. Food and Drug Administration. Furthermore, P&G stated that the nomenclature for the active ingredient/controlled substance had been changed from l-desoxyephedrine to levmetamfetamine. P&G indicated that nothing in the formulation change affects other aspects of the drug delivery system. Based on the application and other information received, including the quantitative composition of the substance and labeling and packaging information, the DEA determined that this product may, under the FD&C Act, be lawfully sold over-the-counter without a prescription. 21 U.S.C. 811(g)(1). In addition, the Deputy Assistant Administrator of the Office of Diversion Control found that the active ingredient in this drug product (levmetamfetamine) is a schedule II controlled substance and is not a narcotic drug as defined by 21 U.S.C. 802(17). The Deputy Assistant Administrator of the Office of Diversion Control therefore found and concluded that this product continues to meet the criteria for exclusion from the CSA pursuant to 21 U.S.C. 811(g)(1). The interim final rule provided an opportunity for interested persons to submit written comments on the rule on or before December 28, 2015. The DEA received one comment in response to the publication of the interim final rule which was a request from P&G for a correction to the spelling of their name. As noted above, the spelling has been corrected in this final rule. This exclusion only applies to the finished drug product in the form of an inhaler (in the exact formulation detailed in the application for exclusion), which is lawfully sold over-the-counter without a prescription under the FD&C Act. The extraction or removal of the active ingredient (levmetamfetamine) from the inhaler shall negate this exclusion and result in the possession of a schedule II controlled substance. Regulatory Analyses Executive Orders 12866 and 13563 This regulation has been developed in accordance with the Executive Orders 12866, ``Regulatory Planning and Review,'' section 1(b) and Executive Order 13563, ``Improving Regulation and Regulatory Review.'' The DEA has determined that this rule is not ``a significant regulatory action,'' and accordingly this rule has not been reviewed by the Office of Management and Budget. As discussed above, this product was previously exempted under a different company name. As discussed in the interim final rule, this action will not have an annual effect on the economy of $100 million or more or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities; create a serious inconsistency or otherwise interfere with an action taken or planned by another agency; materially alter the budgetary impact of entitlements, grants, user fees, or loan programs or the rights and obligations of recipients thereof; or raise novel legal or policy issues arising out of legal mandates, the President's priorities, or the principles set forth in Executive Order 12866. Regulatory Flexibility Analysis The Regulatory Flexibility Act (RFA) (5 U.S.C. 601-612) applies to rules that are subject to notice and comment. The DEA determined, as explained in the interim final rule, that public notice and comment were impracticable and contrary to the public interest. Consequently, the RFA does not apply. Although the RFA does not apply to this rulemaking, the DEA has reviewed the potential impacts of this final rule and determined that it will not have a significant economic impact on a substantial number of small entities. As discussed above and in the interim final rule, this product was previously exempted under a different company name. The Deputy Assistant Administrator, in accordance with the Regulatory Flexibility Act, has reviewed this regulation and by approving it certifies that this regulation will not have a significant economic impact on a substantial number of small entities. Executive Order 12988 This regulation meets the applicable standards set forth in sections 3(a) and 3(b)(2) of Executive Order 12988, ``Civil Justice Reform,'' to eliminate drafting errors and ambiguity, minimize litigation, provide a clear legal standard for affected conduct, and promote simplification and burden reduction. Executive Order 13132 This rulemaking does not have federalism implications warranting the application of Executive Order 13132. The rule does not have substantial direct effects on the States, on the relationship between the Federal Government and the States, or the distribution of power and responsibilities among the various levels of government. Executive Order 13175 This rule does not have tribal implications warranting the application of Executive Order 13175. This rule does not have substantial direct effects on one or more Indian tribes, on the relationship between the Federal Government and Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian tribes. Unfunded Mandates Reform Act of 1995 As stated in the interim final rule, the DEA has determined and certifies pursuant to the Unfunded Mandates Reform Act of 1995 (UMRA), 2 U.S.C. 1501 et seq., that this action would not result in any Federal mandate that may result ``in the expenditure by State, local, and tribal governments, in the aggregate, or by the private sector, of $100,000,000 or more (adjusted for inflation) in any one year * * *.'' Therefore, neither a Small Government Agency Plan nor any other action is required under provisions of the UMRA. Paperwork Reduction Act As stated in the interim final rule, this rule does not impose a new collection of information requirement under the Paperwork Reduction Act, 44 U.S.C. 3501-3521. This action would not impose recordkeeping or reporting requirements on State or local governments, individuals, businesses, or organizations. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. [[Page 6453]] Congressional Review Act This rule is not a major rule as defined by section 804 of the Small Business Regulatory Enforcement Fairness Act of 1996 (Congressional Review Act (CRA)). This rule will not result in: An annual effect on the economy of $100,000,000 or more; a major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions; or significant adverse effects on competition, employment, investment, productivity, innovation, or on the ability of United States-based companies to compete with foreign-based companies in domestic and export markets. List of Subjects in 21 CFR Part 1308 Administrative practice and procedure, Drug traffic control, Reporting and recordkeeping requirements. Accordingly, for the reasons stated above, the interim final rule that was published in the Federal Register on October 27, 2015 (80 FR 65635), is adopted as final with the following change: PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES 0 1. The authority citation for 21 CFR part 1308 continues to read as follows: Authority: 21 U.S.C. 811, 812, 871(b), unless otherwise noted. 0 2. Amend Sec. 1308.22, in the table, by removing the company name, ``Proctor & Gamble Co., The'' and adding in its place ``Procter & Gamble Co., The''. Dated: February 2, 2016. Louis J. Milione, Deputy Assistant Administrator, Office of Diversion Control. [FR Doc. 2016-02403 Filed 2-5-16; 8:45 am] BILLING CODE 4410-09-P
![Federal Register / Vol. 81, No. 25 / Monday, February 8, 2016 / Rules and Regulations 6451
Order 1050.1F, ‘‘Environmental That airspace extending upward from the U.S.C. 801–971. Titles II and III are
Impacts: Policies and Procedures,’’ surface within 3.7 miles each side of the referred to as the ‘‘Controlled
paragraph 5–6.5.a. This airspace action Midwest VOR/DME 215° radial, extending Substances Act’’ and the ‘‘Controlled
is not expected to cause any potentially from the 4.2-mile radius of Wilmington Air Substances Import and Export Act,’’
Park to 7 miles southwest of the airport, and
significant environmental impacts, and within 3.7 miles each side of the Midwest
respectively, and they are collectively
no extraordinary circumstances exist VOR/DME 041° radial extending from the referred to as the ‘‘Controlled
that warrant preparation of an 4.2-mile radius of the airport to 7 miles Substances Act’’ or the ‘‘CSA’’ for the
environmental assessment. northeast of the airport, excluding that purpose of this action. The DEA
portion of airspace within a 1-mile radius of publishes the implementing regulations
Lists of Subjects in 14 CFR Part 71 Hollister Field Airport. for these statutes in title 21 of the Code
Airspace, Incorporation by reference, Issued in Fort Worth, Texas, on January 29, of Federal Regulations (CFR), chapter II.
Navigation (air). 2016. The CSA and its implementing
Robert W. Beck, regulations are designed to prevent,
Adoption of the Amendment detect, and eliminate the diversion of
Manager, Operations Support Group, ATO
In consideration of the foregoing, the Central Service Center.
controlled substances and listed
Federal Aviation Administration chemicals into the illicit market while
[FR Doc. 2016–02284 Filed 2–5–16; 8:45 am]
amends 14 CFR part 71 as follows: ensuring an adequate supply is available
BILLING CODE 4910–13–P
for the legitimate medical, scientific,
PART 71—DESIGNATION OF CLASS A, research, and industrial needs of the
B, C, D, AND E AIRSPACE AREAS; AIR United States. Controlled substances
TRAFFIC SERVICE ROUTES; AND DEPARTMENT OF JUSTICE have the potential for abuse and
REPORTING POINTS dependence and are controlled to
Drug Enforcement Administration protect the public health and safety.
■ 1. The authority citation for part 71 Under the CSA, each controlled
21 CFR Part 1308 substance is classified into one of five
continues to read as follows:
[Docket No. DEA–367] schedules based upon its potential for
Authority: 49 U.S.C. 106(f), 106(g); 40103, abuse, its currently accepted medical
40113, 40120; E.O. 10854, 24 FR 9565, 3 CFR, RIN 1117–AB39
1959–1963 Comp., p. 389.
use in treatment in the United States,
and the degree of dependence the drug
Schedules of Controlled Substances: or other substance may cause. 21 U.S.C.
§ 71.1 [Amended]
Table of Excluded Nonnarcotic 812. The initial schedules of controlled
■ 2. The incorporation by reference in Products: Vicks® VapoInhaler® substances established by Congress are
14 CFR 71.1 of FAA Order 7400.9Z, found at 21 U.S.C. 812(c) and the
Airspace Designations and Reporting AGENCY: Drug Enforcement
Administration, Department of Justice. current list of all scheduled substances
Points, dated August 6, 2015, effective is published at 21 CFR part 1308.
September 15, 2015, is amended as ACTION: Final rule.
The CSA states that the Attorney
follows: General shall by regulation exclude any
SUMMARY: This final rule adopts the
interim final rule, with a correction to nonnarcotic drug which contains a
Paragraph 6002 Class E Airspace
spelling of the manufacturer’s name that controlled substance from the
Designated as Surface Areas.
was published in the Federal Register application of the CSA, if such drug
* * * * * may, under the Federal Food, Drug, and
on October 27, 2015. The Drug
AGL OH E2 Wilmington, OH (Amended) Enforcement Administration is Cosmetic Act (FD&C Act), 21 U.S.C. 301
Wilmington, Wilmington Air Park, OH amending the table of Excluded et seq., be lawfully sold over-the-
(Lat. 39°25′41″ N., long. 083°47′32″ W.) Nonnarcotic Products to update the counter without a prescription. 21
Wilmington, Hollister Field Airport, OH listing for Vicks® VapoInhaler®, U.S.C. 811(g)(1). Such exclusions apply
(Lat. 39°26′15″ N., long. 083°42′30″ W.) containing 50 mg levmetamfetamine in only to specific nonnarcotic drugs
Within a 4.2-mile radius of Wilmington Air a nasal decongestant inhaler, marketed following suitable application to the
Park, and within 3.7 miles each side of the by The Procter & Gamble Company. DEA in accordance with 21 CFR
Midwest VOR/DME 215° radial extending This over-the-counter, non-narcotic 1308.21. The current table of Excluded
from the 4.2-mile radius of Wilmington Air Nonnarcotic Products is found in 21
Park to 7 miles southwest of the airport, and
drug product is excluded from
provisions of the Controlled Substances CFR 1308.22. The authority to exclude
within 3.7 miles each side of the Midwest such substances has been delegated to
VOR/DME 041° radial extending from the Act.
4.2-mile radius of the airport to 7 miles
the Administrator of the DEA, 28 CFR
DATES: This final rule is effective on
northeast of the airport, excluding that 0.100, and redelegated to the Deputy
February 8, 2016.
portion of airspace within a 1-mile radius of Assistant Administrator of the Office of
FOR FURTHER INFORMATION CONTACT: Diversion Control, section 7 of 28 CFR
Hollister Field Airport.
Barbara J. Boockholdt, Office of part 0, appendix to subpart R.
* * * * * Diversion Control, Drug Enforcement
Paragraph 6004 Class E Airspace Areas Administration; Mailing Address: 8701 Background
Designated as an Extension to a Class D or Morrissette Drive, Springfield, Virginia This final rule adopts, with a change
Class E Surface Area. 22152; Telephone: (202) 598–6812. to the spelling of the manufacturer’s
asabaliauskas on DSK5VPTVN1PROD with RULES
* * * * * SUPPLEMENTARY INFORMATION: name, the interim final rule, ‘‘Schedules
AGL OH E4 Wilmington, OH (Amended) of Controlled Substances: Table of
Legal Authority Excluded Nonnarcotic Products: Vicks®
Wilmington, Wilmington Air Park, OH
(Lat. 39°25′41″ N., long. 083°47′32″ W.) The Drug Enforcement VapoInhaler® ’’ that was published in
Wilmington, Hollister Field Airport, OH Administration (DEA) implements and the Federal Register on October 27,
(Lat. 39°26′15″ N., long. 083°42′30″ W.) enforces titles II and III of the 2015. 80 FR 65635. The correct spelling
Midwest VOR/DME Comprehensive Drug Abuse Prevention of the manufacturer’s name is ‘‘The
(Lat. 39°25′47″ N., long. 083°48′04″ W.) and Control Act of 1970, as amended. 21 Procter & Gamble Company.’’ The
VerDate Sep<11>2014 16:19 Feb 05, 2016 Jkt 238001 PO 00000 Frm 00041 Fmt 4700 Sfmt 4700 E:\FR\FM\08FER1.SGM 08FER1](https://thefederalregister.org/doc/81_FR_6476/page/1.svg)
![Federal Register / Vol. 81, No. 25 / Monday, February 8, 2016 / Rules and Regulations 6453
Congressional Review Act SUMMARY: This final rule adopts, nonnarcotic drug which contains a
This rule is not a major rule as without change, the interim final rule controlled substance from the
defined by section 804 of the Small that was published in the Federal application of the CSA, if such drug
Business Regulatory Enforcement Register on October 27, 2015. The Drug may, under the Federal Food, Drug, and
Fairness Act of 1996 (Congressional Enforcement Administration is Cosmetic Act (FD&C Act), 21 U.S.C. 301
Review Act (CRA)). This rule will not amending the table of Excluded et seq., be lawfully sold over-the-
result in: An annual effect on the Nonnarcotic Products to update the counter without a prescription. 21
economy of $100,000,000 or more; a company name for the drug product U.S.C. 811(g)(1). Such exclusions apply
major increase in costs or prices for Nasal Decongestant Inhaler/Vapor only to specific nonnarcotic drugs
consumers, individual industries, Inhaler (containing 50 milligrams following suitable application to the
Federal, State, or local government levmetamfetamine) to Aphena Pharma DEA in accordance with 21 CFR
agencies, or geographic regions; or Solutions—New York, LLC. This over- 1308.21. The current table of Excluded
significant adverse effects on the-counter, nonnarcotic drug product is Nonnarcotic Products is found in 21
competition, employment, investment, excluded from the provisions of the CFR 1308.22. The authority to exclude
productivity, innovation, or on the Controlled Substances Act. such substances has been delegated to
ability of United States-based DATES: This final rule is effective on the Administrator of the DEA, 28 CFR
companies to compete with foreign- February 8, 2016. 0.100, and redelegated to the Deputy
based companies in domestic and FOR FURTHER INFORMATION CONTACT: Assistant Administrator of the Office of
export markets. Barbara J. Boockholdt, Office of Diversion Control, section 7 of 28 CFR
Diversion Control, Drug Enforcement part 0, appendix to subpart R.
List of Subjects in 21 CFR Part 1308
Administration; Mailing Address: 8701 Background
Administrative practice and Morrissette Drive, Springfield, Virginia
procedure, Drug traffic control, This final rule adopts, without
22152; Telephone: (202) 598–6812.
Reporting and recordkeeping change, the interim final rule,
SUPPLEMENTARY INFORMATION: ‘‘Schedules of Controlled Substances:
requirements.
Accordingly, for the reasons stated Legal Authority Table of Excluded Nonnarcotic
above, the interim final rule that was Products: Nasal Decongestant Inhaler/
The Drug Enforcement
published in the Federal Register on Vapor Inhaler’’ that was published in
Administration (DEA) implements and
October 27, 2015 (80 FR 65635), is the Federal Register on October 27,
enforces titles II and III of the
adopted as final with the following 2015. 80 FR 65632.
Comprehensive Drug Abuse Prevention On December 10, 2013, pursuant to
change: and Control Act of 1970, as amended. 21 the application process of § 1308.21, the
U.S.C. 801–971. Titles II and III are DEA received correspondence from
PART 1308—SCHEDULES OF referred to as the ‘‘Controlled
CONTROLLED SUBSTANCES Aphena Pharma Solutions—New York,
Substances Act’’ and the ‘‘Controlled LLC (Aphena Pharma) stating that it had
Substances Import and Export Act,’’ acquired Classic Pharmaceuticals LLC
■ 1. The authority citation for 21 CFR
respectively, and they are collectively and requesting that the current
part 1308 continues to read as follows:
referred to as the ‘‘Controlled exclusion for the drug product Nasal
Authority: 21 U.S.C. 811, 812, 871(b), Substances Act’’ or the ‘‘CSA’’ for the
unless otherwise noted. Decongestant Inhaler/Vapor Inhaler be
purpose of this action. The DEA transferred to Aphena Pharma. Aphena
■ 2. Amend § 1308.22, in the table, by publishes the implementing regulations Pharma also stated that the
removing the company name, ‘‘Proctor for these statutes in title 21 of the Code manufacturing process (i.e., facility) and
& Gamble Co., The’’ and adding in its of Federal Regulations (CFR), chapter II. the formulation for the drug product
place ‘‘Procter & Gamble Co., The’’. The CSA and its implementing
Nasal Decongestant Inhaler/Vapor
Dated: February 2, 2016. regulations are designed to prevent,
Inhaler had not changed.
Louis J. Milione, detect, and eliminate the diversion of Based on the application and other
controlled substances and listed information received, the DEA
Deputy Assistant Administrator, Office of
Diversion Control. chemicals into the illicit market while determined that this product may,
ensuring an adequate supply is available under the FD&C Act, be lawfully sold
[FR Doc. 2016–02403 Filed 2–5–16; 8:45 am]
for the legitimate medical, scientific, over-the-counter without a prescription.
BILLING CODE 4410–09–P
research, and industrial needs of the 21 U.S.C. 811(g)(1). In addition, the
United States. Controlled substances Deputy Assistant Administrator of the
DEPARTMENT OF JUSTICE have the potential for abuse and Office of Diversion Control found that
dependence and are controlled to the active ingredient in this drug
Drug Enforcement Administration protect the public health and safety. product (levmetamfetamine) is a
Under the CSA, each controlled
schedule II controlled substance 1 and is
21 CFR Part 1308 substance is classified into one of five
not a narcotic drug as defined by 21
schedules based upon its potential for
[Docket No. DEA–409] U.S.C. 802(17). The Deputy Assistant
abuse, its currently accepted medical
Administrator of the Office of Diversion
RIN 1117–ZA30 use in treatment in the United States,
Control therefore found and concluded
and the degree of dependence the drug
that this drug product continues to meet
asabaliauskas on DSK5VPTVN1PROD with RULES
Schedules of Controlled Substances: or other substance may cause. 21 U.S.C.
Table of Excluded Nonnarcotic the criteria for exclusion from the CSA
812. The initial schedules of controlled
Products: Nasal Decongestant Inhaler/ pursuant to 21 U.S.C. 811(g)(1).
substances established by Congress are The interim final rule provided an
Vapor Inhaler found at 21 U.S.C. 812(c) and the opportunity for interested persons to
AGENCY: Drug Enforcement current list of all scheduled substances
Administration, Department of Justice. is published at 21 CFR part 1308. 1 Levmetamfetamine is controlled in schedule II
The CSA states that the Attorney of the CSA because it is an isomer of
ACTION: Final rule.
General shall by regulation exclude any methamphetamine.
VerDate Sep<11>2014 16:19 Feb 05, 2016 Jkt 238001 PO 00000 Frm 00043 Fmt 4700 Sfmt 4700 E:\FR\FM\08FER1.SGM 08FER1](https://thefederalregister.org/doc/81_FR_6476/page/3.svg)
Document Created: 2016-02-06 00:24:51
Document Modified: 2016-02-06 00:24:51
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Rules and Regulations | |
| Action | Final rule. | |
| Dates | This final rule is effective on February 8, 2016. | |
| Contact | Barbara J. Boockholdt, Office of | |
| FR Citation | 81 FR 6451 | |
| RIN Number | 1117-AB39 | |
| CFR Associated | Administrative Practice and Procedure; Drug Traffic Control and Reporting and Recordkeeping Requirements |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR